Why the study?
The treatment of HFpEF has represented a clinical management challenge, but the discovery of SGLT2i as cardiac protectors brought new treatment possibilities.
Does SGLT2i improve primary outcomes in patients with heart failure with preserved ejection fraction (HFpEF)?
Does SGLT2i improve primary outcomes in patients with heart failure with preserved ejection fraction (HFpEF)?
This review evaluates the role of SGLT2 inhibitors in the management of heart failure with preserved ejection fraction, driven by major trials like EMPEROR-Preserved and DELIVER.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Gomes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: